Ann: Meet the CEO Investor Presentation, page-3

Orthocell is a company with big dreams, without approvals thats all they will be, this year, next year, it wont really matter, With 20 million in the bank, they are ready for the next stage, commercialism. I know we have said approvals around the corner so, so, so may times, we are closer than we were last year ?
Most orther biotechs were in the same boat five years ago dreaming, than all of a sudden approvals FDA,TGA and the share price goes up, up, up, up, up and in no time their investors were making ten, twenty time their money, institutional companies took notice and bought 20 / 50% of the company pushing the retail investor down to about 30%, the same thing will happen to Orthocell because retail investors are happy with double their money, so they take the profit and run . Sure the top 20 holders and institutional investors need to hold a bigger parcel in Orthocell this will happen after APPROVALS
You have to remember its not their money they are buying with so they dont care if they buy at five dollars, they want to see a return on their five dollars and without approvals its just too much of a risk